Pliva: Two Steps Forward, One Step Back?

After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.

By Christopher Morrison

By licensing co-promotion rights to the overactive bladder (OAB) treatment trospium (Sanctura) from Indevus Pharmaceuticals Inc. in April 2004,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo